Abstract:Whether differences between naive cell-derived primary (1°) and memory cell-derived secondary (2°) CD4+ T-cell effectors contribute to protective recall responses is unclear. Here, we compare these effectors directly after influenza A virus infection. Both develop with similar kinetics, but 2° effectors accumulate in greater number in the infected lung and are the critical component of memory CD4+ T-cell–mediated protection against influenza A virus, independent of earlier-acting memory-cell helper functions. … Show more
“…Consistent with this possibility that effector molecules secreted by primary and secondary effector CD4 ϩ T cells are distinct, comparative microarray analysis of the two subsets revealed approximately 450 differentially expressed genes (90). The signaling pathways between the two CD4 ϩ T cell effector types were also found to be different (90). Another recent study also demonstrated how the innate immune response was specifically modified for enhanced protection by memory T cells in both a systemic and a mucosal model of recall response (91).…”
Section: Memory In the Innate Immune Compartmentmentioning
confidence: 57%
“…In a recall response, the differential interaction could lower the activation threshold of the innate cells and allow them to rapidly upregulate their antimicrobial effector response. Consistent with this possibility that effector molecules secreted by primary and secondary effector CD4 ϩ T cells are distinct, comparative microarray analysis of the two subsets revealed approximately 450 differentially expressed genes (90). The signaling pathways between the two CD4 ϩ T cell effector types were also found to be different (90).…”
Section: Memory In the Innate Immune Compartmentmentioning
A major impediment to tuberculosis (TB) vaccine development is the lack of reliable correlates of immune protection or biomarkers that would predict vaccine efficacy. Gamma interferon (IFN-␥) produced by CD4 ؉ T cells and, recently, multifunctional CD4 ؉ T cells secreting IFN-␥, tumor necrosis factor (TNF), and interleukin-2 (IL-2) have been used in vaccine studies as a measurable immune parameter, reflecting activity of a vaccine and potentially predicting protection. However, accumulating experimental evidence suggests that host resistance against Mycobacterium tuberculosis infection is independent of IFN-␥ and TNF secretion from CD4 ؉ T cells. Furthermore, the booster vaccine MVA85A, despite generating a high level of multifunctional CD4؉ T cell response in the host, failed to confer enhanced protection in vaccinated subjects. These findings suggest the need for identifying reliable correlates of protection to determine the efficacy of TB vaccine candidates. This article focuses on alternative pathways that mediate M. tuberculosis control and their potential for serving as markers of protection. The review also discusses the significance of investigating the natural human immune response to M. tuberculosis to identify the correlates of protection in vaccination.
“…Consistent with this possibility that effector molecules secreted by primary and secondary effector CD4 ϩ T cells are distinct, comparative microarray analysis of the two subsets revealed approximately 450 differentially expressed genes (90). The signaling pathways between the two CD4 ϩ T cell effector types were also found to be different (90). Another recent study also demonstrated how the innate immune response was specifically modified for enhanced protection by memory T cells in both a systemic and a mucosal model of recall response (91).…”
Section: Memory In the Innate Immune Compartmentmentioning
confidence: 57%
“…In a recall response, the differential interaction could lower the activation threshold of the innate cells and allow them to rapidly upregulate their antimicrobial effector response. Consistent with this possibility that effector molecules secreted by primary and secondary effector CD4 ϩ T cells are distinct, comparative microarray analysis of the two subsets revealed approximately 450 differentially expressed genes (90). The signaling pathways between the two CD4 ϩ T cell effector types were also found to be different (90).…”
Section: Memory In the Innate Immune Compartmentmentioning
A major impediment to tuberculosis (TB) vaccine development is the lack of reliable correlates of immune protection or biomarkers that would predict vaccine efficacy. Gamma interferon (IFN-␥) produced by CD4 ؉ T cells and, recently, multifunctional CD4 ؉ T cells secreting IFN-␥, tumor necrosis factor (TNF), and interleukin-2 (IL-2) have been used in vaccine studies as a measurable immune parameter, reflecting activity of a vaccine and potentially predicting protection. However, accumulating experimental evidence suggests that host resistance against Mycobacterium tuberculosis infection is independent of IFN-␥ and TNF secretion from CD4 ؉ T cells. Furthermore, the booster vaccine MVA85A, despite generating a high level of multifunctional CD4؉ T cell response in the host, failed to confer enhanced protection in vaccinated subjects. These findings suggest the need for identifying reliable correlates of protection to determine the efficacy of TB vaccine candidates. This article focuses on alternative pathways that mediate M. tuberculosis control and their potential for serving as markers of protection. The review also discusses the significance of investigating the natural human immune response to M. tuberculosis to identify the correlates of protection in vaccination.
“…Whether the provision of help by peptide-primed CD4 memory leads to more rapid clearance and protection is unclear. There are many effector functions of CD4 T cells that facilitate protection from influenza virus infection, including potentiation of the early innate response and direct cytotoxicity (6,24,38,80,81; reviewed in references [82][83][84][85]. We expect that the latter two functions of CD4 T cells may be carried out by cells reactive to peptides derived from many viral proteins, including HA, NA, NP, and M1, because these proteins are synthesized or available in many cells within the lung.…”
Section: Discussionmentioning
confidence: 99%
“…The issue of whether CD4 frequency is predictive of a B cell response has yet to be well established though recent evidence is accumulating that suggests a close relationship (21,22). Endogenous or adoptively transferred memory CXCR5 ϩ CD4 T cells can accelerate the B cell response to a model protein antigen (23) and have also been shown to have "superior" functionality in the lymph node (LN) and lung of infected mice (24). In humans, CXCR5-expressing cells in the blood are functionally related to Tfh cells, perhaps representing the memory component of these B cell helpers (25,26).…”
Influenza virus vaccination strategies are focused upon the elicitation of protective antibody responses through administration of viral protein through either inactivated virions or live attenuated virus. Often overlooked in this strategy is the CD4 T cell response: how it develops into memory, and how it may support future primary B cell responses to heterologous infection. Through the utilization of a peptide-priming regimen, this study describes a strategy for developing CD4 T cell memory with the capacity to robustly expand in the lung-draining lymph node after live influenza virus infection. Not only were frequencies of antigen-specific CD4 T cells enhanced, but these cells also supported an accelerated primary B cell response to influenza virusderived protein, evidenced by high anti-nucleoprotein (NP) serum antibody titers early, while there is still active viral replication ongoing in the lung. NP-specific antibody-secreting cells and heightened frequencies of germinal center B cells and follicular T helper cells were also readily detectable in the draining lymph node. Surprisingly, a boosted memory CD4 T cell response was not sufficient to provide intermolecular help for antibody responses. Our study demonstrates that CD4 T cell help is selective and limiting to the primary antibody response to influenza virus infection and that preemptive priming of CD4 T cell help can promote effective and rapid conversion of naive B cells to mature antibody-secreting cells.
“…In lymphoid organs, secondary germinal centres are thought to be formed by reactivated IgM+ memory B‐cells, providing a blank canvas for antibody class switching relevant to the pathogen 73. In influenza virus‐infected mice, CD4 T‐cells and B‐cells can be found in clusters within the lung, and many virus‐specific B‐cells in the lung are class switched 74, 75. This suggests that germinal centres formed in ELS in peripheral tissues may follow different rules to those in lymphoid organs following re‐infection.…”
Section: Memory Cd4 T‐cells Are Found Throughout the Bodymentioning
SummaryImmunological memory provides rapid protection to pathogens previously encountered through infection or vaccination. CD4 T‐cells play a central role in all adaptive immune responses. Vaccines must, therefore, activate CD4 T‐cells if they are to generate protective immunity. For many diseases, we do not have effective vaccines. These include human immunodeficiency virus (HIV), tuberculosis and malaria, which are responsible for many millions of deaths each year across the globe. CD4 T‐cells play many different roles during the immune response coordinating the actions of many other cells. In order to harness the diverse protective effects of memory CD4 T‐cells, we need to understand how memory CD4 T‐cells are generated and how they protect the host. Here we review recent findings on the location of different subsets of memory CD4 T‐cells that are found in peripheral tissues (tissue resident memory T‐cells) and in the circulation (central and effector memory T‐cells). We discuss the generation of these cells, and the evidence that demonstrates how they provide immune protection in animal and human challenge models.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.